Endocyte Signs Agreement With Bristol-Myers Squibb Company To Develop And Commercialize Folate-Targeted Chemotherapeutic Agents

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Jan. 5, 2006--Endocyte, Inc. announced it has licensed to Bristol-Myers Squibb Company (NYSE:BMY) Endocyte's vitamin-targeting technology to target Bristol-Myers Squibb's proprietary epothilone cancer chemotherapeutic agents. The license is a result of an ongoing collaborative research effort between the two companies to create novel folate conjugates of Bristol-Myers Squibb's proprietary epothilone compounds.